Literature DB >> 31276602

Optimising low-dose methotrexate for rheumatoid arthritis-A review.

Catherine J Lucas1,2,3, Simon B Dimmitt1,4, Jennifer H Martin1,2,3.   

Abstract

Methotrexate at low doses (5-25 mg/week) is first-line therapy for rheumatoid arthritis. However, there is inter- and intrapatient variability in response, with contribution of variability in concentrations of active polyglutamate metabolites, associated with clinical efficacy and toxicity. Prescribing remains heterogeneous across population groups, disease states and regimens. This review examines current knowledge of dose-response of oral methotrexate in the setting of rheumatoid arthritis, and how this could help inform dosage regimens.
© 2019 The British Pharmacological Society.

Entities:  

Keywords:  clinical pharmacology; methotrexate; pharmacodynamics; pharmacokinetics; prescribing; rheumatoid arthritis

Mesh：

Substances：

Year:  2019        PMID： 31276602      PMCID： PMC6783593          DOI： 10.1111/bcp.14057

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  90 in total

Review 1.  Subcutaneous administration of methotrexate at high doses makes a better performance in the treatment of rheumatoid arthritis compared with oral administration of methotrexate: A systematic review and meta-analysis.

Authors:  Donghai Li; Zhouyuan Yang; Pengde Kang; Xiaowei Xie
Journal:  Semin Arthritis Rheum       Date:  2015-12-01       Impact factor: 5.532

2.  Indispensable or intolerable? Methotrexate in patients with rheumatoid and psoriatic arthritis: a retrospective review of discontinuation rates from a large UK cohort.

Authors:  Elena Nikiphorou; Andra Negoescu; John D Fitzpatrick; Calum T Goudie; Andrew Badcock; Andrew J K Östör; Anshuman P Malaviya
Journal:  Clin Rheumatol       Date:  2014-03-09       Impact factor: 2.980

3.  Severe pancytopenia associated with low-dose methotrexate therapy for rheumatoid arthritis.

Authors:  J M Calvo-Romero
Journal:  Ann Pharmacother       Date:  2001-12       Impact factor: 3.154

4.  Subcutaneous administration of methotrexate with a prefilled autoinjector pen results in a higher relative bioavailability compared with oral administration of methotrexate.

Authors:  Uwe Pichlmeier; Kay-Uwe Heuer
Journal:  Clin Exp Rheumatol       Date:  2014-07-01       Impact factor: 4.473

5.  Adverse effects of low dose methotrexate therapy in rheumatoid arthritis.

Authors:  R J McKendry; P Dale
Journal:  J Rheumatol       Date:  1993-11       Impact factor: 4.666

6.  The relationship of hepatotoxic risk factors and liver histology in methotrexate therapy for juvenile rheumatoid arthritis.

Authors:  P J Hashkes; W F Balistreri; K E Bove; E T Ballard; M H Passo
Journal:  J Pediatr       Date:  1999-01       Impact factor: 4.406

Review 7.  Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review.

Authors:  S L Whittle; R A Hughes
Journal:  Rheumatology (Oxford)       Date:  2004-01-06       Impact factor: 7.580

Review 8.  Polymorphisms and Pharmacogenomics for the Clinical Efficacy of Methotrexate in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis.

Authors:  Qi Qiu; Jing Huang; Xiaoming Shu; Huizheng Fan; Youwen Zhou; Cheng Xiao
Journal:  Sci Rep       Date:  2017-03-07       Impact factor: 4.379

9.  Dissect new mechanistic insights for geniposide efficacy on the hepatoprotection using multiomics approach.

Authors:  Shi Qiu; Aihua Zhang; Tianlei Zhang; Hui Sun; Yu Guan; Guangli Yan; Xijun Wang
Journal:  Oncotarget       Date:  2017-10-19

10.  Risk factors for oral methotrexate failure in patients with inflammatory polyarthritis: results from a UK prospective cohort study.

Authors:  James Bluett; Jamie C Sergeant; Alex J MacGregor; Jacqueline R Chipping; Tarnya Marshall; Deborah P M Symmons; Suzanne M M Verstappen
Journal:  Arthritis Res Ther       Date:  2018-03-20       Impact factor: 5.156
View more
  8 in total

Review 1.  Why maximum tolerated dose?

Authors:  Hans G Stampfer; Genevieve M Gabb; Simon B Dimmitt
Journal:  Br J Clin Pharmacol       Date:  2019-07-22       Impact factor: 4.335

2.  Tyrosine kinase inhibitors (TKIs) used in the management of chronic myeloid leukaemia are associated with haematologic toxicities-Which TKI is the safest?

Authors:  Ahmet Emre Eşkazan
Journal:  Br J Clin Pharmacol       Date:  2019-08-22       Impact factor: 4.335

Review 3.  Optimising low-dose methotrexate for rheumatoid arthritis-A review.

Authors:  Catherine J Lucas; Simon B Dimmitt; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2019-08-09       Impact factor: 4.335

4.  Effect of Missed Doses on the Therapeutic Effect of Methotrexate for Rheumatoid Arthritis: A Pharmacokinetic Modeling Study.

Authors:  Alan Morrison; Melissa E Stauffer; Anna S Kaufman
Journal:  Open Access Rheumatol       Date:  2021-09-14

5.  Evaluation of Ovarian Reserve in Women With Rheumatoid Arthritis.

Authors:  Sara Patricia Peña-Lizola; Luis Humberto Sordia-Hernandez; Selene Marysol Garcia-Luna; Otto Valdes-Martinez; Cassandra Michele Skinner-Taylor; Mario Alberto Garza-Elizondo; Oscar Vidal-Gutierrez; Jesus Zacarias Villarreal-Perez; Miryam Eguia-Bernal; Felipe Arturo Morales-Martinez
Journal:  J Family Reprod Health       Date:  2021-12

6.  A Randomized Open-Labeled Trial of Methotrexate as a Steroid-Sparing Agent for Patients With Generalized Myasthenia Gravis.

Authors:  Li Di; Faxiu Shen; Xinmei Wen; Yan Lu; Wenjia Zhu; Min Wang; Yuwei Da
Journal:  Front Immunol       Date:  2022-03-18       Impact factor: 7.561

7.  Nanoenzyme engineered neutrophil-derived exosomes attenuate joint injury in advanced rheumatoid arthritis via regulating inflammatory environment.

Authors:  Lei Zhang; Ziguo Qin; Han Sun; Xiang Chen; Jian Dong; Siyu Shen; Liming Zheng; Ning Gu; Qing Jiang
Journal:  Bioact Mater       Date:  2022-03-23

8.  Structural Deformation of MTX Induced by Nanodrug Conjugation Dictate Intracellular Drug Transport and Drug Efficacy.

Authors:  Jun-Young Park; Ja-Shil Hyun; Jun-Goo Jee; Sung Jean Park; Dongwoo Khang
Journal:  Int J Nanomedicine       Date:  2021-07-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.